Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2011; 57(3): 16-24

The frequency ofallelic polymorphism of matrix gla-protein gene in acute coronary syndrome patients

V.Yu. Garbuzova, V.L. Gurianova, A.N. Parkhomenko, V.E. Dosenko, A.V. Ataman.

    Сум. ун-т;Ін-т фізіології ім. О.О.Богомольця НАН України, Київ;Нац. наук. центр “Інститут кардіології імені академіка М.Д. Стражеска” НАМН України, Київ


Abstract

Allelic polymorphisms of matrix Gla protein (MGP) gene were determinated in 115 patients with acute coronary syn­drome (ACS) and in 110 practically healthy people. It was shown that interrelation of major homozygotes, heterozy-gotes and minor homozygotes by T-^C MGP promoter polymorphism in patients with ACS were 59,8%, 32,7%, 7,5% and in control 58.7%, 36.7%, 4.6% (P > 0.05 by X2-test); by G—A polymorphism: 42.1%, 45.6%, 12.3% and 41.8%, 54.5%, 3.6% correspondingly (P < 0,05); and by Thr ^Ala exon 4 polymorphism: 42.6%, 43.5%, 13.9% compared to 43.9%, 45.9%, 10.2% in control (P > 0.05). The obtained data show that MGP A/A variant of MGP promoter G^A poly­morphism is a risk factor of ACS in Ukrainian population. These data indicate also that the intensity of calcification influences atherosclerotic injury of coronary artery.

Keywords: матриксный Gla-протеин, однонуклео-тидный полиморфизм, инфаркт миокарда

Full text: (PDF, in Ukrainian)

References

  1. Price P.A., Urist M.R., Otawara Y. Matrix Gla pro­tein, a new г-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone // Biochem. Biophys. Res. Commun. - 1983. - 117. -P. 765-771.
  2. Fraser J.D., Price P.A. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein // J. Biol. Chem. - 1988. - 263. -P. 11033-11036.
  3. Price P.A., Faus S.A., Williamson M.K. Warfarin-iduced artery calcification is accelerated by growth and vitamin D // Arterioscler. Thromb. Vasc. Biol. - 2000. -20. - P. 317-327.4. Price P.A., Williamson M.K. Primary structure of bo­vine matrix Gla protein, a new vitamin K-dependent bone protein // J. Biol. Chem. - 1985. - 260. -P. 14971-14975.
  4. Proudfoot D., Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla pro­tein // Nephrology (Carlton). - 2006. - 11. - P. 455-461.
  5. Cancela L., Hsiehg C.-L., Francket U., Price P.A. Mo­lecular structure, chromosome assignment, and pro­moter organization of the human matrix Gla protein gene // J. Biol. Chem. - 1990. - 265. - P. 15040-15048.
  6. Herrmann S.M., Whatling C, Brand E., Nikaud V., Gariepy J., Simon A., Evans A., Ruidavets L.B., Arveiler D., Luc G., Tiret L., Henney A., Cambien F. Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction // Arterioscler. Thromb. Vasc. Biol. - 2000. -20. - P. 2386-2393.
  7. Farzaneh-Far A., Davies J.D., Braam L.A., Spronk H.M., Proudfoot D., Chan S.W., O’Shaughnessy K.M., Weissberg P.L., Vermeer C, Shanaham CM. A Poly­morphism of the human matrix г-carboxyglutamic acid protein promoter alters binding of an activating pro-tein-1 complex and is associated with altered transcrip­tion and serum levels // J. Biol. Chem. - 2001. - 276. -P. 32466-32473.
  8. 9. Kobayashi N., Kitazawa R., Maeda S., Schurgers L.J., Kitazawa S. T-138C polymorphism of matrix Gla pro­tein promoter alters its expression but is not directly associated with atherosclerotic vascular calcification // Kobe J. Med. Sci. - 2004. - 50. - P. 69-81.
  9. 10. Brancaccio D., Biondi M.L., Gallieni M., Turri O., Galassi A., Cecchini F., Russo D., Andreucci V., Cozzolino M. Matrix GLA protein gene polymor­phisms: clinical correlates and cardiovascular mortal­ity in chronic kidney disease patients // Amer. J. Nephrol. - 2005. - 25. - P. 548-552.
  10. Hernandez-Pacheco G., Murguia L.E., Rodriguez-Pe­rez J.M., Fragoso J.M., Perez-Vielma N., Martinez-Rodriguez N., Granados J., Vargas-Alarcyn G. Matrix gamma-carboxyglutamic acid protein (MGP) G-7A and T-138C gene polymorphisms in Indian (Mayo and Teenek) and Mestizo populations from Mexico // Hum. Biol. - 2005. - 77. - P. 385-391.
  11. Taylor B.C., Schreiner P.J., Doherty T.M., Fornage M., Carr J.J., Sidney S. Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study // Hum. Genet. - 2005. - 116. - P. 525-528.
  12. Crosier M.D., Booth S.L., Peter I., Dawson-Hughes B., Price P.A., O’Donnell C.J., Hoffmann U., Wiilliamson M.K., Ordovas J.M. Matrix Gla protein polymorphisms are associated with coronary artery calcification // J. Nutr. Sci. Vitaminol. - 2009. - 55. - P. 59-65.
  13. Schurgers L.J., Teunissen K.J.F., Knapen M.H.J., Kwaijtaal M., van Diest R., Appels A., Reutelingsperger C.P., Cleutjens J.P.M., Vermeer C. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein // Arterioscler. Thromb. Vasc. Biol. – 2005. – 25. – P. 1629–1633.
  14. Stanford W. Coronary artery calcification as an indica­tor of preclinical coronary artery disease // Radiogra-phics. – 1999. – 19. – P. 1409–1419.
  15. Shanahan C.M., Proudfoot D., Tyson K.L., Cary N. R. B., Edmonds M., Weissberg P. L. Expression of mineralisation-regulating proteins in association with human vascular calcification // Z. Kardiol. – 2000. – 89, Suppl. 2. – P. II/63–II/68.
  16. Giachelli C.M. Vascular calcification mechanisms // J. Amer. Soc. Nephrol. – 2004. – 15. – P. 2959–2964.
  17. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment el­evation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology // Eur. Heart J. – 2002. – 23. – P.1809–1840.
  18. 19. Antman E.M., Hand M., Armstrong P.W., Bates E.R., Green L.A., Halasyamani L.K., Hochman J.S., Krumholz H.M., Lamas G.A., Mullany C.J., Pearle D.L., Sloan M.A., Smith S.C. Jr; 2004 Writing Committee Members, Anbe D.T., Kushner F.G., Ornato J.P., Jacobs A.K., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., Ettinger S.M., Halperin J.L., Hunt S.A., Lytle B.W., Nishimura R., Page R.L., Riegel B., Tarkington L.G., Yancy C.W. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction // J. Amer. Coll. Cardiol. – 2004. – 44. – P.E1–211.
  19. 20. Thygesen K., Alpert J.S., White H.D.; Joint ESC/ACCF/ AHA/WHF Task Force for the Redefinition of Myocar-dial Infarction, Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., Chaitman B., Clemmensen P.M., Dellborg M., Hod H., Porela P., Underwood R., Bax J.J., Beller G.A., Bonow R., Van der Wall E.E., Bassand J.P., Wijns W., Ferguson T.B., Steg P.G., Uretsky B.F., Williams D.O., Armstrong P.W., Antman E.M., Fox K.A., Hamm C.W., Ohman E.M., Simoons M.L., Poole-Wilson P.A., Gurfinkel E.P., Lopez-Sendon J.L., Pais P., Mendis S., Zhu J.R., Wallentin L.C., Fernandez-Aviles F., Fox K.M., Parkhomenko A.N., Priori S.G., Tendera M., Voipio-Pulkki L.M., Vahanian A., Camm A.J., De Caterina R., Dean V. , Dickstein K., Filippatos G., Funck-Brentano C., Hellemans I., Kristensen S.D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P. , Zamorano J.L., Morais J., Brener S., Harrington R., Morrow D., Lim M., Martinez-Rios M.A., Steinhubl S., Levine G.N., Gibler W.B., Goff D., Tubaro M., Dudek D., Al-Attar N. Universal definition of myocardial infarction // European Heart J. – 2007. – 28. – P.2525–2538.
  20. Braam L.A., Dissel P., Gijsbers B.L., Spronk H.M.H., Hamulyak K., Soute B.A.M., Debie W., Vermeer C. As­say for human matrix Gla protein in serum. Potentialapplications in the cardiovascular field // Arterioscler. Thromb. Vasc. Biol. – 2000. – 20. – P. 1257–1261.
  21. Jono S., Vermeer C., Dissel P. , Hasegava K., Shioi A., Taniwaki H., Kizu A., Nishizawa Y., Saito S. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography // Thromb. Haemost. – 2004. – 91. – P. 790–794.
  22. O’Donnell C.J., Kyla Shea M., Price P.A., Gagnon D.R., Wilson P.W.F., Larson M.G., Kiel D.P., Hoffmann U., Ferencik M., Clouse M.E., Williamson M.K., Cupples L.A., Dawson-Hughes B., Booth S.L. Matrix Gla protein is associated with risk factors for athero­sclerosis but not with coronary artery calcification) // Arterioscler. Thromb. Vasc. Biol. – 2006. – 26. – P. 2769–2774.
  23. Krueger T., Westenfeld R., Schurgers L.J., Brandenburg V.M. Coagulation meets calcification: The vitamin K system // Int. J. Artif. Organs. – 2009. – 32. – P. 67–74.
  24. Wallin R., Schurgers L., Wajih N. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification // Thromb. Res. – 2008. – 122. – P. 411–417.
  25. Uotila L. The metabolic functions and mechanism of action of vitamin K // Scand. J. Clin. Lab. Invest. – 1990. – 201, Suppl. – P. 109–117.
  26. Abedin M., Tintut Y. , Demer L.L. Vascular calcification. Mechanisms and clinical ramifications // Arterioscler. Thromb. Vasc. Biol. – 2004. – 24. – P. 1161–1170.
  27. Doherty T.M., Fitzpatrick L.A., Inoue D., Qiao J.H., Fishbein M.C., Detrano R.C., Shah P.K., Rajavashisth T.B. Molecular, endocrine, and genetic mechanisms of arterial calcification // Endocrine Rev. – 2004. – 25. – P. 629–672.
  28. 29. Shao J.S., Cai J., Towler D.A. Molecular mechanisms of vascular calcification: lessons learned from the aorta // Arterioscler. Thromb. Vasc. Biol. – 2006. – 26. – P. 1423–1430.
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.